- Home
- SLNH vs GALT Comparison
SLNH vs GALT Comparison
Compare SLNH & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLNH | GALT |
|---|---|---|
| Founded | 1961 | 2000 |
| Country | United States | United States |
| Employees | 52 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 297.0M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | SLNH | GALT |
|---|---|---|
| Price | $1.26 | $2.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 13.1M | 539.5K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.42 | $2.03 |
| 52 Week High | $5.14 | $7.13 |
Technical Indicators
Market Signals| Indicator | SLNH | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 39.64 |
| Support Level | $1.25 | $2.75 |
| Resistance Level | $1.43 | $3.35 |
| Average True Range (ATR) | 0.12 | 0.42 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 57.50 | 1.77 |
Price Performance
Historical ComparisonAbout SLNH Soluna Holdings Inc.
Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.